B of A Securities Downgrades Ventas to Neutral, Lowers Price Target to $62
B of A Securities analyst Joshua Dennerlein downgrades Ventas (NYSE:VTR) from Buy to Neutral and lowers the price target from $66 to $62.
RBC Capital Maintains Outperform on Ventas, Raises Price Target to $65
RBC Capital analyst Michael Carroll maintains Ventas (NYSE:VTR) with a Outperform and raises the price target from $62 to $65.
A Look Into Ventas Debt
Over the past three months, shares of Ventas (NYSE:VTR) rose by 8.17%. Before we understand the importance of debt, let us look at how much debt Ventas has.
Stocks That Hit 52-Week Highs On Tuesday
Before 10 a.m. ET on Tuesday, 125 stocks hit new 52-week highs.
Raymond James Maintains Outperform on Ventas, Raises Price Target to $65
Raymond James analyst Jonathan Hughes maintains Ventas (NYSE:VTR) with a Outperform and raises the price target from $61 to $65.
Wolfe Research Initiates Coverage On Ventas with Outperform Rating, Announces Price Target of $71
Wolfe Research analyst Andrew Rosivach initiates coverage on Ventas (NYSE:VTR) with a Outperform rating and announces Price Target of $71.
5 Reasons Why Omega Healthcare Investors Is A Health Care REIT To Watch
Omega Healthcare Investors (NYSE: OHI) is a health care REIT that owns a portfolio of skilled nursing and senior housing facilities that are triple-net leased to third-party operators.
Stocks That Hit 52-Week Highs On Monday
During Monday's morning session, 255 companies made new 52-week highs.